Flu Vaccine Breakthrough: Targeting Two Proteins Could Halt Airborne Spread
For decades, vaccine development has centered on a critical question: should vaccines prioritize stopping a virus from replicating within an infected person, or from spreading to others? Novel research from Penn State suggests we may not have to choose. A study published March 13 in Science Advances demonstrates a strategy to simultaneously reduce viral transmission and limit replication in animal models.
The Hemagglutinin and Neuraminidase Duo
The research focuses on influenza and the virus’s two key surface proteins: hemagglutinin (HA) and neuraminidase (NA). Scientists discovered that building immunity against both proteins, rather than focusing on just one, significantly reduces the likelihood of airborne viral spread. This finding could revolutionize future vaccine design.
“This suggests that intentionally targeting these two proteins together in future vaccines could assist curb spread,” explained Troy Sutton, lead author of the study and Huck Early Career Chair in Virology at Penn State. “Critically, transmission was reduced without accelerating viral evolution inside the host, which is a key concern in vaccine design.”
How the Study Worked: A Ferret Model
Researchers utilized ferrets – chosen for their respiratory systems’ similarity to humans – to model influenza transmission. Infected “donor” ferrets were paired with uninfected “contact” ferrets in shared-air cages. By monitoring viral shedding, transmission rates, and viral evolution, the team could assess how immunity to HA, NA, or both impacted the spread of the H1N1 influenza virus.
The results were clear: animals with immunity to both proteins were consistently less likely to transmit the virus. Transmission rates dropped by half, with both HA and NA immune responses contributing equally to the reduction. A measurable threshold was also identified – when viral levels fell below a certain point early in infection, the chance of transmission dropped below 50%.
No Evidence of Viral Escape
A significant finding was the lack of viral evolution to evade immunity. Across numerous animal models, no consistent “escape variants” – virus mutations that bypass immune protection – emerged when targeting both HA and NA. This suggests that a dual-protein approach doesn’t necessarily drive rapid viral adaptation, a common concern with vaccine development.
Implications for Future Vaccine Strategies
The study reinforces the growing consensus that influenza vaccines may need to move beyond solely triggering strong antibody responses. Future vaccines might need to actively blunt viral spread at the source by targeting multiple viral proteins.
“Our perform strengthens the growing consensus among experts that influenza vaccines need to target multiple influenza virus proteins to be maximally effective,” Sutton stated. “Vaccines of the future may need to do more than trigger strong antibody responses. They may need to blunt spread at the source and that may signify doubling up on the immune targets the virus relies on most.”
The Global Impact of Influenza
Influenza remains a significant global health threat. The World Health Organization estimates that seasonal influenza viruses, including H1N1, infect up to 1 billion people annually, leading to 3 to 5 million cases of severe illness and up to 650,000 deaths each year.
Frequently Asked Questions
Q: What are hemagglutinin and neuraminidase?
A: These are proteins on the surface of the influenza virus that are essential for infection and spread. HA helps the virus enter cells, even as NA helps it release new virus particles.
Q: Why are ferrets used in this research?
A: Ferrets have respiratory systems remarkably similar to humans, making them a great model for studying influenza infection and transmission.
Q: Does this mean a new flu vaccine is coming soon?
A: This research provides a strong foundation for developing more effective vaccines, but further research and clinical trials are needed before a new vaccine becomes available.
Q: What is a viral escape variant?
A: A viral escape variant is a mutation in the virus that allows it to evade the immune protection provided by a vaccine or prior infection.
Did you know? Bacterial viruses, called bacteriophages, are also being investigated as potential alternatives to antibiotics, highlighting the ongoing battle between viruses and bacteria.
Pro Tip: Staying up-to-date with your annual flu vaccine remains the best way to protect yourself and others from influenza.
Explore more research from Penn State’s Huck Institutes of the Life Sciences here.
Worth a look